Familial Primary Pulmonary Hypertension - Epidemiology Forecast - 2032

January 2022 | 60 pages | ID: FA628D63BC04EN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Familial Primary Pulmonary Hypertension - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Familial Primary Pulmonary Hypertension epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Familial Primary Pulmonary Hypertension Understanding

The DelveInsight Familial Primary Pulmonary Hypertension epidemiology report gives a thorough understanding of the Familial Primary Pulmonary Hypertension by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Familial Primary Pulmonary Hypertension in the US, Europe, and Japan. The report covers the detailed information of the Familial Primary Pulmonary Hypertension epidemiology scenario in seven major countries (US, EU5, and Japan).

Familial Primary Pulmonary Hypertension Epidemiology Perspective by DelveInsight

The Familial Primary Pulmonary Hypertension epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Familial Primary Pulmonary Hypertension epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Familial Primary Pulmonary Hypertension epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Familial Primary Pulmonary Hypertension Detailed Epidemiology Segmentation

The Familial Primary Pulmonary Hypertension epidemiology covered in the report provides historical as well as forecasted Familial Primary Pulmonary Hypertension epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Familial Primary Pulmonary Hypertension report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Familial Primary Pulmonary Hypertension report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Familial Primary Pulmonary Hypertension Epidemiology Report and Model provide an overview of the global trends of Familial Primary Pulmonary Hypertension in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Familial Primary Pulmonary Hypertension in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Familial Primary Pulmonary Hypertension
• The report provides the segmentation of the Familial Primary Pulmonary Hypertension epidemiology

Report Highlights

• 11-year Forecast of Familial Primary Pulmonary Hypertension epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Familial Primary Pulmonary Hypertension
• Cases of Familial Primary Pulmonary Hypertension by Mutation Types
• Familial Primary Pulmonary Hypertension Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Familial Primary Pulmonary Hypertension?
• What are the key findings pertaining to the Familial Primary Pulmonary Hypertension epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Familial Primary Pulmonary Hypertension across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Familial Primary Pulmonary Hypertension?
• What are the currently available treatments of Familial Primary Pulmonary Hypertension?

Reasons to buy

The Familial Primary Pulmonary Hypertension Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Familial Primary Pulmonary Hypertension market
• Quantify patient populations in the global Familial Primary Pulmonary Hypertension market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Familial Primary Pulmonary Hypertension therapeutics in each of the markets covered
• Understand the magnitude of Familial Primary Pulmonary Hypertension population by its epidemiology
• The Familial Primary Pulmonary Hypertension Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF FAMILIAL PRIMARY PULMONARY HYPERTENSION

3. FAMILIAL PRIMARY PULMONARY HYPERTENSION: DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Familial Primary Pulmonary Hypertension Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Familial Primary Pulmonary Hypertension Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Familial Primary Pulmonary Hypertension Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Familial Primary Pulmonary Hypertension Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Familial Primary Pulmonary Hypertension Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Familial Primary Pulmonary Hypertension Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Familial Primary Pulmonary Hypertension Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Familial Primary Pulmonary Hypertension Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Familial Primary Pulmonary Hypertension Treatment and Management
6.2. Familial Primary Pulmonary Hypertension Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Familial Primary Pulmonary Hypertension Epidemiology in 7MM (2019-2032)
Table 2: Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Familial Primary Pulmonary Hypertension Epidemiology in the United States (2019-2032)
Table 4: Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Familial Primary Pulmonary Hypertension Epidemiology in Germany (2019-2032)
Table 6: Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Familial Primary Pulmonary Hypertension Epidemiology in France (2019-2032)
Table 8: Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Familial Primary Pulmonary Hypertension Epidemiology in Italy (2019-2032)
Table 10: Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Familial Primary Pulmonary Hypertension Epidemiology in Spain (2019-2032)
Table 12: Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Familial Primary Pulmonary Hypertension Epidemiology in the United Kingdom (2019-2032)
Table 14: Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Familial Primary Pulmonary Hypertension Epidemiology in Japan (2019-2032)
Table 16: Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Familial Primary Pulmonary Hypertension Epidemiology in 7MM (2019-2032)
Figure 2 Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Familial Primary Pulmonary Hypertension Epidemiology in the United States (2019-2032)
Figure 4 Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Familial Primary Pulmonary Hypertension Epidemiology in Germany (2019-2032)
Figure 6 Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Familial Primary Pulmonary Hypertension Epidemiology in France (2019-2032)
Figure 8 Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Familial Primary Pulmonary Hypertension Epidemiology in Italy (2019-2032)
Figure 10 Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Familial Primary Pulmonary Hypertension Epidemiology in Spain (2019-2032)
Figure 12 Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Familial Primary Pulmonary Hypertension Epidemiology in the United Kingdom (2019-2032)
Figure 14 Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Familial Primary Pulmonary Hypertension Epidemiology in Japan (2019-2032)
Figure 16 Familial Primary Pulmonary Hypertension Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report